Xcout Intel
Crucible Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Crucible Therapeutics among biotechnology companies — ranked by similarity to what Crucible Therapeutics actually does, not by market-cap band.
Subscribe to see Crucible Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Crucible Therapeutics
Crucible Therapeutics is a biopharmaceutical company founded in 2023 to develop novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, originating from research at the Sheffield Institute for Translational Neuroscience.
Crucible Therapeutics at a glance
Crucible Therapeutics is a biotechnology company. Its most recent funding round, Seed, closed in January 2023. Xcout tracks 2 named people at Crucible Therapeutics, including Cliff Holloway (Chief Executive Officer).
Crucible Therapeutics leadership
- Cliff HollowayChief Executive Officer
- Neill Moray MackenzieExecutive Chairman of the Board and Entrepreneur-in-Residence at Argobio Studios
Crucible Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Crucible Therapeutics competitors
Ranked by semantic similarity — how close each company is to Crucible Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Harness Therapeutics Ltd. is a biotechnology company founded in 2023 and based in Cambridge, United Kingdom. The company focuses on RNA biology and the development of novel therapeutics for the treatment of neurodegenerative diseases.
Life Sciences
Libra Therapeutics is a biopharmaceutical company headquartered in Del Mar, California, focused on developing novel disease-modifying therapeutics. The company aims to restore cellular balance and improve lysosomal function to halt neurodegeneration in conditions such as amyotrophic lateral sclerosis.
Similar biotechnology company
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Healthcare & Life Sciences
Rinri Therapeutics is a private biotechnology company headquartered in Sheffield, South Yorkshire, United Kingdom. Founded in 2018, the firm focuses on regenerative medicine research to develop first-in-class therapeutics for treating hearing loss and neurological conditions.
Similar biotechnology company
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Biotech
Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead drug candidate, pridopidine, has been studied in Huntington’s disease and amyotrophic lateral sclerosis (ALS), serving patients with serious neurological conditions.
Biotech
AcuraStem Inc. is a biotechnology company founded in 2016 and headquartered in Pasadena, California, focused on developing potential therapies for neurodegenerative diseases like ALS.
Similar biotechnology company
Amygdala Neurosciences Inc is an independent small biopharmaceutical company headquartered in San Francisco, California. Its mission is to invent and develop first-in-class therapeutics.
Similar biotechnology company
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
Similar biotechnology company
Atalanta Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, focused on developing RNA-interference therapeutic interventions for neurodegenerative diseases. The company launched with significant venture backing from life sciences investors.
Similar biotechnology company
Aclipse Therapeutics is a clinical-stage biopharmaceutical company that develops novel, disease-modifying drug candidates for severe and life-threatening conditions such as gastroparesis and amyotrophic lateral sclerosis (ALS). The company leverages genomic, proteomic, and biomarker data to target molecular pathways involving inflammation, cellular stress, and protein misfolding, while also implementing patient stratification approaches to improve clinical outcomes.
Life Sciences
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company founded in 2011 and headquartered in Boston, Massachusetts. The company focuses on developing novel treatments for devastating neurological conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Crucible Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Crucible Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →